Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

Part of paid clinical trials in Los Angeles, California.

Sponsor: University of Southern California
Study ID: NCT00183859
Phase: PHASE1
Status: Completed

Conditions

Adenocarcinoma
Gastric Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

irinotecan — DRUG
Intraperitoneal Irinotecan given every three weeks

Study Details

This is a research study for patients that have an advanced cancer that is confined mostly to the abdominal cavity and have failed treatment with conventional therapy, or for which no standard treatment exists. The purpose of this study is to determine the dose of a chemotherapy drug (called irinotecan) that can be administered safely into the abdominal cavity. We also wish to identify the side effects of irinotecan when it is administered directly into the abdomen. In this study, we will also determine the levels of irinotecan in the blood and in the abdominal cavity. Irinotecan is a chemotherapy drug that can decrease the size of several different tumors. It is approved by the FDA for the treatment of colon cancer. It appears that some other chemotherapy drugs are more effective and may have less side effects when they are administered directly into the abdomen.